Cheaters

A New Generation of Corporate Tax Traitors

By Phil Mattera, Dirt Diggers Digest

A scene we'd all like to see

Large U.S.-based corporations have long demonstrated that they are willing to put profits before patriotism. 

Over the past two decades, about two dozen of those companies have moved their legal headquarters offshore in order to drastically reduce their federal tax obligations. 

This disreputable practice is once again in vogue and being brought to a new level by Pfizer’s effort to acquire AstraZeneca and register the combined operation in the United Kingdom. The big Walgreen drugstore chain is also considering a foreign reincorporation move.

During the last big wave of what are politely known as corporate inversions, there was a great deal of protest. The decision by companies such as Tyco International and Ingersoll-Rand to reincorporate abroad was widely denounced as being akin to treason. Reacting to the controversy, Stanley Works dropped plans for a similar move.

Today there is surprisingly little anger over Pfizer’s plan. In fact, the business press is filled with articles indicating that numerous other companies are thinking along the same lines. Pfizer is facing some opposition, but it is mainly in Britain, where the company’s CEO Ian Read (photo) was grilled by members of parliament concerned that the merger will have a negative impact on employment at AstraZeneca.

While Pfizer has been quite open about the tax dodging aspect of its takeover bid, companies involved in inversions tend to justify their move by emphasizing the global nature of their business. 

The problem with this argument is that it is not supported by the facts. The companies that reincorporate abroad continue to do more business in the United States than in any other country. For example, the purportedly Irish company Ingersoll-Rand derives 59 percent of its revenues from the United States and has 80 percent of its long-lived assets in that country.

Inverted companies usually continue to trade on U.S. stock exchanges and keep their real headquarters at home. They also continue to win contract awards from the federal government. Accenture, another company claiming to be Irish, does more than $1 billion a year in business with Uncle Sam.

Along with their federal tax avoidance, many of the turncoat companies also take widespread advantage of tax breaks and other economic development subsidies from state and local governments. Here are some of the aggregate totals assembled by my colleagues and me at Good Jobs First for our Subsidy Tracker database:

• Eaton: $101 million
• Pentair: $33.2 million
• Accenture: $15.4 million
• Tyco International: $13.9 million
• Delphi Automotive: $9.6 million
• Ingersoll-Rand: $5.6 million

If Pfizer succeeds in its bid, it would add another $200 million to this list, plus $9.2 million that has gone to AstraZeneca’s U.S. operations. Walgreen has received more than $12 million in subsidies.

Along with showing little loyalty to the United States, the corporate tax traitors do not hesitate to abandon their adopted countries when it is financially advantageous to do so. A number of the companies that had reincorporated in Bermuda and the Cayman Islands in the late 1990s and early 2000s subsequently moved to Europe. These include Ingersoll-Rand, Tyco International and Seagate Technology.

Doing so allowed them to avoid the stigma and legal complications of being based in Caribbean tax havens while still enjoying the relatively low corporate tax rates provided by countries such as Ireland and Switzerland. Britain, the intended new home of Pfizer, is now also regarded as one of the more respectable tax haven destinations.

While pretending to be Irish or Swiss or British may be regarded as more acceptable than pretending to be Bermudan, what these companies are doing is still brazen tax dodging and a betrayal of the country that helped them grow into corporate behemoths in the first place.

After the inversion controversies of the early 2000s, Congress took action that thwarted the practice.

In today’s political climate in Washington, it is unlikely that restrictions will be placed on the new generation of runaway corporations. Business apologists are already using the Pfizer deal not as a call to arms to block more relocations but rather as an argument for giving in to longstanding demands to gut what remains of the corporate income tax.

According to this warped logic, the United States will solve the tax haven problem only by becoming one itself.